304 related articles for article (PubMed ID: 23478672)
1. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
Ma YC; Yang JY; Yan LN
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
[TBL] [Abstract][Full Text] [Related]
2. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.
Chan AW; Tong JH; Chan SL; Lai PB; To KF
Histopathology; 2014 Jun; 64(7):935-50. PubMed ID: 24506513
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.
Fan QM; Jing YY; Yu GF; Kou XR; Ye F; Gao L; Li R; Zhao QD; Yang Y; Lu ZH; Wei LX
Cancer Lett; 2014 Oct; 352(2):160-8. PubMed ID: 24892648
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
5. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
Sun YF; Xu Y; Yang XR; Guo W; Zhang X; Qiu SJ; Shi RY; Hu B; Zhou J; Fan J
Hepatology; 2013 Apr; 57(4):1458-68. PubMed ID: 23175471
[TBL] [Abstract][Full Text] [Related]
6. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.
Zhong C; Wu JD; Fang MM; Pu LY
Tumour Biol; 2015 Sep; 36(10):7623-30. PubMed ID: 25921286
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi.
Yu XH; Xu LB; Liu C; Zhang R; Wang J
Dig Dis Sci; 2011 Jan; 56(1):252-9. PubMed ID: 20437099
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
11. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis.
Kim H; Choi GH; Na DC; Ahn EY; Kim GI; Lee JE; Cho JY; Yoo JE; Choi JS; Park YN
Hepatology; 2011 Nov; 54(5):1707-17. PubMed ID: 22045674
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
14. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
15. OV6⁺ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma.
Yang W; Wang C; Lin Y; Liu Q; Yu LX; Tang L; Yan HX; Fu J; Chen Y; Zhang HL; Tang L; Zheng LY; He YQ; Li YQ; Wu FQ; Zou SS; Li Z; Wu MC; Feng GS; Wang HY
J Hepatol; 2012 Sep; 57(3):613-20. PubMed ID: 22612999
[TBL] [Abstract][Full Text] [Related]
16. Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater.
Piscuoglio S; Lehmann FS; Zlobec I; Tornillo L; Dietmaier W; Hartmann A; Wünsch PH; Sessa F; Rümmele P; Baumhoer D; Terracciano LM
J Clin Pathol; 2012 Feb; 65(2):140-5. PubMed ID: 22130902
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinomas expressing 'stemness'-related markers: clinicopathological characteristics.
Kim H; Park YN
Dig Dis; 2014; 32(6):778-85. PubMed ID: 25376296
[TBL] [Abstract][Full Text] [Related]
18. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.
Chen YL; Lin PY; Ming YZ; Huang WC; Chen RF; Chen PM; Chu PY
BMC Cancer; 2017 Jul; 17(1):474. PubMed ID: 28687090
[TBL] [Abstract][Full Text] [Related]
19. Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma.
Bae JS; Noh SJ; Jang KY; Park HS; Chung MJ; Park CK; Moon WS
Int J Oncol; 2012 Dec; 41(6):2150-8. PubMed ID: 22993038
[TBL] [Abstract][Full Text] [Related]
20. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.
Terris B; Cavard C; Perret C
J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
